EKF Diagnostics Investor Announcements

EKF announces that it has purchased a total of 750,000 of its ordinary shares at a price of 44.1667 pence per share

EKF has purchased a total of 900,000 of its ordinary shares at a price of 44.6667 pence per share.

EKF has purchased a total of 1,300,000 of its ordinary shares at an average price of 45.0962 pence per share

EKF announces that it intends to conduct on-market purchases under a share buyback programme

Final results for the year ended 31 December 2021. 

Additional enzyme production capacity to accelerate EKF’s organic growth strategy

EKF notes the announcements released by Verici Dx plc on 4 March 2022 relating to the successful Placing for Verici Dx, a developer of advanced clinical diagnostics for organ transplant.

EKF will announce its preliminary results for the year ended 31 December 2021 on Tuesday 29 March 2022.

EKF announces the appointment of Jenny Winter as Non-executive Director (“NED”), effective on 1 February 2022. At the same time Carl Contadini, Non-executive Director, will stand down from the Board.

EKF confirms that continued strong trading will result in its performance for the financial year ended 31 December 2021, including adjusted EBITDA, being ahead of already upgraded market expectations.